Biotin-DAG Peptide
Biotin-CDAGRKQKC-acid, (Disulfide bridge: Cys1 – Cys9)
Description
Application Data
Description
-
Cyclic DAG peptide which targets the matricellular protein CTGF/CCN2, present at high levels in many diseased states of the brain
Application Data
-
Data Sheet Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1000886 Molecular Weight 1231.5 Sequence (one letter code) Biotin-CDAGRKQKC-acid, (Disulfide bridge: Cys1 – Cys9)
Sequence (three letter code) Biotin-Cys-Asp-Ala-Gly-Arg-Lys-Gln-Lys-Cys-OH, (Disulfide bridge: Cys1 – Cys9)
Modifications (Disulfide bridge: Cys1-Cys9) Purity >95% Storage -20°C References Mann et al., (2017). Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer’s disease. Nat Commun. 8: 1403. PMID: 29123083
Scodeller and Asciutto (2020). Targeting Tumors Using Peptides. Molecules. 25(4): 808. PMID: 32069856
Manufactured in: United Kingdom Cyclic DAG peptide targets connective tissue growth factor (CTGF/CCN2), present in the extracellular matrix, endothelial cells and overexpressed in several brain diseases.
CTGF is a matricellular protein that acts as a regulator of several cellular functions, including cell adhesion, migration, mitogenesis, differentiation, and survival. CTGF is up regulated in Alzheimer’s disease, Parkinson’s disease, brain injury, glioblastoma, and cerebral infarction.
DAG peptide has been shown to home to the brain in mouse models of glioblastoma, traumatic brain injury, and Parkinson’s disease when exogenously delivered, making it an attractive target for the treatment of glioblastoma. DAG may be of use as a tool to enhance delivery of therapeutics and imaging agents to sites of brain diseases.